Mutant parasites for use as vaccines and platforms for screening for compounds
US8962265B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jun 6, 2011 |
| Grant date | Feb 24, 2015 |
| Priority date | — |
| Expiry date | Jun 6, 2031 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2500/04
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Cloning and characterization of a TgIF2α kinase from Toxoplasma gondii designated TgIF2K-D illustrates that this protein is related to GCN2, an eIF2α kinase known to respond to nutrient starvation in other organisms. TgIF2K-D is present in the cytosol of both intra- and extracellular Toxoplasma and facilitates translational control through TgIF2α phosphorylation in extracellular parasites. Both a TgIF2K-D knockout parasite and a parasite harboring the TgIF2α mutant (S71A substitution) exhibited loss of eIF2α kinase activity which manifested itself as significant fitness defect. Accordingly, eIF2α phosphorylation and translational control are an important mechanism by which vulnerable extracellular parasites protect themselves which searching for a new host cell. TgIF2K-D is an excellent target for development of compounds and therapies that can be used to treat infections caused by Toxoplasma and other eukaryotic parasites, especially parasites that have high homology or identity to TgIF2K-D.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.